Skip to main content
Article thumbnail
Location of Repository

Growth hormone producing prolactinoma in juvenile cystinosis: a simple coincidence?

By Martine T. P. Besouw, Elena N. Levtchenko, Michèl A. A. P. Willemsen and Kees Noordam


Juvenile cystinosis was diagnosed in a patient who presented with severe headache attacks and photophobia. Treatment with oral cysteamine and topical cysteamine eye drops was started. One-and-a-half years later, he developed unilateral gynecomastia and elevated prolactin and growth hormone levels. A pituitary macroprolactinoma was discovered and successfully treated with the dopamine agonist cabergoline. Increased serum growth hormone levels were attributed to enhanced growth hormone production by the prolactinoma and somatostatin inhibition by cysteamine. Although the occurrence of prolactinoma in this patient could be a simple coincidence, it might also be a rare yet unrecognised complication of cystinosis

Topics: Brief Report
Publisher: Springer-Verlag
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1985). Blunted prolactin response to thyrotropin-releasing hormone stimulation in cystinotic children receiving cysteamine.
  2. (1996). Clinical polymorphism of cystinosis encephalopathy. Results of treatment with cysteamine.
  3. (2003). Clinical presentation and outcome of pituitary adenomas in teenagers.
  4. (1987). Cysteamine therapy for children with nephropathic cystinosis.
  5. (2001). Cystinosis: a disorder of lysosomal membrane transport. In: Scriver
  6. (1977). Endocrine studies in cystinosis: compensated primary hypothyroidism.
  7. (2004). Idiopathic intracranial hypertension in cystinosis.
  8. (1994). Molecular genetic studies of sporadic pituitary tumors.
  9. (1982). Nonabsorptive hydrocephalus associated with nephropathic cystinosis.
  10. (1980). Pituitary resistance to thyroid hormone in cystinosis.
  11. (1993). Pituitarytesticular function in nephropathic cystinosis.
  12. (1997). Prolactinomas. In: Sheaves
  13. (1981). Somatostatin in rat tissues is depleted by cysteamine administration.
  14. (2007). Valvular heart disease and the use of dopamine agonists for Parkinson’s disease.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.